Navigation Links
Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019
Date:8/26/2009

SARASOTA, Fla., Aug. 26 /PRNewswire-FirstCall/ -- Roper Industries, Inc. (NYSE: ROP) announced today that it proposes to offer, subject to market and other considerations, senior unsecured notes due 2019. Actual terms of the notes, including interest rate, principal amount and maturity, will depend on market conditions at the time of pricing.

Net proceeds from the sale of the notes will be used to repay borrowings under Roper's senior unsecured credit facility and for other general corporate purposes.

Banc of America Securities LLC, J.P. Morgan Securities Inc. and Wells Fargo Securities, LLC are serving as joint book-running managers for the offering.

Full details of the offering, including a description of the notes and certain risk factors related to the notes, are contained in a preliminary prospectus supplement dated August 26, 2009 and related base shelf prospectus dated July 29, 2008 available through Banc of America Securities LLC, Prospectus Department, 100 W. 33rd St., 3rd Floor, New York, New York, 10001, e-mail: dg.prospectus_distribution@bofasecurities.com, telephone: 1-800-294-1322; J.P. Morgan Securities Inc., Investment Grade Syndicate Desk, 270 Park Ave. 8(th) Floor, New York, New York, 10017, telephone: 212-834-4533 or fax: 212-834-6081; and Wells Fargo Securities, LLC, Customer Information Center, Attn: Syndicate Operations, 1525 West W.T. Harris Blvd., Charlotte, NC 28262-0675, telephone: 800-326-5897, e-mail: '/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Greenway Medical Technologies PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers
2. "Being a Proper Man is About Having a 'tache" Says Keith Lemon
3. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
4. Knowing What to Look for Can Aid in Proper Diagnosis & Treatment of Mild Traumatic Brain Injuries
5. Nexicon Partners With IntentionQuest to Protect Intellectual Property Rights of Self Help Industry
6. EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
7. Resvera Health Rx Launches All-Natural Resveratrol-Based Supplement with Anti-Aging and Disease-Fighting Properties
8. Court Slaps Former Officials of SEIU-UHW with Preliminary Injunction After Finding They Filched and Sabotaged Union Property in Effort to Create a New Union
9. Proper Physician-Relationship Management Ensures Hospital Stability and Vitality
10. Partnership Collaborates on HIE for Interoperability of Electronic Health Records and Patient Data in Ohio
11. Digitizing Health Records Not Enough; Integrated, Interoperable Enterprises Vital to U.S. Healthcare Transformation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)... Benton Communications announces a highly...em for retailers struggling to make an economic re...r 26, 2009 -- Flu fears is the type of challenge t...cy room, according to Dr. David Benton, business g...ness growth system – The Rfactor Intensive ...
(Date:11/25/2009)...ndCALGARY,Nov.25/PRNewswire/-SentinelleMedicalInc....I)coilsandsoftwareandCalgaryScientificInc.,aleadin...ucedawebversionofAegis(TM)Breast4DAdvancedVisualiz...irsttrulyzero-footprintWebclientbasedmedicalimagin...)platformallowsforzero-footprintaccess-requiringno...
(Date:11/25/2009)...ISCO,Nov.25/PRNewswire/--TheBayAreaAirQualityManag...pare the Air Alert forThursday,November...anyothersolidfuel,bothindoorsandoutdoors. ,, "C...ytomorrow,"saidJackBroadbent,executiveofficerofthe...hehealthoftheirneighborsandfellowcommunitymemberst...
(Date:11/25/2009)...crease blood pressure? This simple question has b... New Stress-related gene Modulates High Blood Pres...essure? This simple question has been the focus o...ch has for the first time established a link betwe... response to stress in mice as well as humans. The...
(Date:11/25/2009)...plagued by neurological symptoms, study finds , ...Neurological side effects are among the potential ...r cancer who were treated with cisplatin-based che...ncluded 1,409 Norwegian men treated for unilateral...part in a follow-up survey conducted from 1998 to ...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2
...ern Medical College at Dallas report that contact ...xygen transmissible materials are expected to redu...han contact lenses which are available now. Based ...ar.// The results of the Southeastern study ar...
...he hair loss associated with drug treatment for ca...apy-induced alopecia (CIA), is a frequent side eff...g for patients at a vulnerable time in their lives...s with a skull cap to cool the scalp, minimising b...
...ion that is to blame for most panic attacks and ot...breakthrough could lead to the development of drug...ated that more than one in twelve people suffer fr...hobia. They found that 92% of the affected family ...
...rst clues to the high failure rate of cloning and ...ore of the nucleus.The discovery, announced at the...e Advancement of Science in Washington, shows that...ogether.// "Our genes are not uniformly distr...
...lder people avert a form of arthritis that can cha...lking an impossible one.Those who regularly walked...bilities to perform activities of daily living. ...elying on others for help// in these ordinary acti...
...screening technique for persons suffering from typ...rch Fund says investigations of skin lesions may a...rom a group of cancers, particularly those of the ...yposis colorectal cancer syndrome - it may be poss...
Other Medicine News:Health News:New contact lens materials 2Health News:Breakthrough in cancer therapy 2Health News:The anxiety gene, 2Health News:DNA and clones 2Health News:Arthritis risk reduced by exercise 2
(Date:11/25/2009)...25/PRNewswire-FirstCall/--HeskaCorporation(HSKA);(...specialtyproductstotheveterinaryindustry,announced...hesupplyofbloodgasproductsandaffiliatedconsumables...wscom.com/cgi-bin/prnh/20000622/HESKALOGO ) ,, ...efieldofadvancedpoint-of-carediagnostics,"commente...
(Date:11/25/2009)...Newswire/--BioTrendsResearchGroup,Inc.releasedWave...rstinamulti-phasesyndicatedmarketresearchprojecttr...omproductlaunchthroughthefirstsixmonthsofavailabil...tionfrom75uniqueDermatologistsandqualitativeinform...Stelara,obstaclestouse,typicalpatienttypes,product...
(Date:11/25/2009)...ov.25/PRNewswire/--RegadoBiosciences,aprivatelyhel...erswithactivecontrolagents,announcedthatDavidMazzo...fray21stAnnualHealthCareConferenceattheNewYorkPala...ivenat1:10pm(EST)onTuesday,December1andwillinclude...eaddevelopmentprogram,theanticoagulantsystem,REG1....
Breaking Medicine Technology:Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 1Michael S Burg Appointed as Co Lead Counsel in the Yasmin Yaz Multidistrict Litigation 61325 2Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 1Esperion Therapeutics Initiates Phase I Clinical Study for ETC 1002 14833 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 1ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 2ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 3ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 4ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 5ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 6ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 7ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 8ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 9ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 10ReSearch Pharmaceutical Services Inc Unaudited Quarterly Report for the Period Ended September 30 2009 6258 11
...AM, England, October 7 ,Sosei Group Corporation ("... plc ("Vectura"; LSE: VEC), announce results of tw... and tolerability of NVA237 presented at the,annua...S) in Berlin,Germany. The new data show that NVA23...cting muscarinic antagonist (LAMA), provides susta...
...pens the door to the understanding of and possible... and cancer, BILLERICA, Mass., Oct. 6 Seahorse B... ever analytical instrument for the,kinetic measur...plasmic,glycolysis in cells in a 96 well microplat...lar bioenergetics have been relatively unchanged s...
Other Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3
STELLARA™
...m Thermo Labsystems was designed specifically to c... Advanced features such as the new fast dial syst...es help to define this as a new leader in single c...ate offers a custom fit for different hand sizes. ...
Corning Lambda Single Channel Pipettor, 0.1-2.5 ul
...s improved ergonomics for today's exacting laborat...finger rest and the large display windows enhance ...als also feature soft-touch tip ejection with powe... blow-out for 0.2 - 50ul micro volume pipetting. F...
Medicine Products: